BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $108 at BMO Capital
August 5, 2020 9:46 AM EDTBMO Capital analyst George Farmer raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $108.00 (from $94.00) while maintaining a Market Perform rating.
The analyst commented, "Following model adjustments, we increase our PT to $108 from $94 and maintain our Market Perform rating ahead... More
BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats
August 4, 2020 4:16 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $430 million versus the consensus estimate of $418.61 million.
GUIDANCE:
BioMarin Pharma sees 2020 revenue of $1.85-1.95 billion, versus the consensus of $1.9... More
